“Follow-On” Biologics Guidance Will Limit Use Of Data To “Public Domain”
Executive Summary
FDA's upcoming draft guidance on follow-on biologics will allow use of data that are in the public domain only, Center for Drug Evaluation & Research acting Director Steven Galson, MD, told the Schwab Soundview Washington Research Group health care conference May 5
You may also be interested in...
European Biosimilar Guidelines May Leave Room For Regulatory Shortcuts
Marketing authorization for generic biologics may be extrapolated to additional indications approved for the reference product, according to biosimilar guidelines recently released by the European Medicines Agency
European Biosimilar Guidelines May Leave Room For Regulatory Shortcuts
Marketing authorization for generic biologics may be extrapolated to additional indications approved for the reference product, according to biosimilar guidelines recently released by the European Medicines Agency
Follow-On Biologics Will Rely On “Case-By-Case” Approach – Rep. Waxman
FDA's development of a guidance for follow-on versions of insulin and human growth hormone will be a key milestone in demonstrating the agency's ability to implement a "case-by-case" approach to "generic" biologics, Rep. Henry Waxman (D-Calif.) said